Astrazeneca PLC (NYSE:AZN) Given Consensus Rating of “Buy” by Analysts
Astrazeneca PLC (NYSE:AZN) has earned an average recommendation of “Buy” from the twenty-five analysts that are presently covering the company. Three equities research analysts have rated the stock with a sell recommendation, eight have issued a hold recommendation, eleven have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $38.69.
AZN has been the subject of a number of research reports. Shore Capital restated a “hold” rating on shares of Astrazeneca PLC in a report on Wednesday, July 27th. Bank of America Corp. reiterated a “buy” rating and set a $36.65 price objective on shares of Astrazeneca PLC in a report on Monday, July 18th. Citigroup Inc. reiterated a “buy” rating on shares of Astrazeneca PLC in a report on Friday, September 23rd. Berenberg Bank reiterated a “buy” rating on shares of Astrazeneca PLC in a report on Sunday, September 11th. Finally, Beaufort Securities reiterated a “hold” rating on shares of Astrazeneca PLC in a report on Friday, August 26th.
Shares of Astrazeneca PLC (NYSE:AZN) traded down 0.5720% on Monday, reaching $32.1053. 2,618,359 shares of the company were exchanged. The company’s 50 day moving average is $33.23 and its 200 day moving average is $30.79. Astrazeneca PLC has a 12-month low of $26.97 and a 12-month high of $35.04. The firm has a market capitalization of $81.23 billion, a PE ratio of 36.6918 and a beta of 0.75.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/10/astrazeneca-plc-nyseazn-given-consensus-rating-of-buy-by-analysts.html
Astrazeneca PLC (NYSE:AZN) last posted its quarterly earnings results on Thursday, July 28th. The company reported $0.83 EPS for the quarter, topping analysts’ consensus estimates of $0.76 by $0.07. The business earned $5.60 billion during the quarter, compared to analysts’ expectations of $5.56 billion. Astrazeneca PLC had a net margin of 9.23% and a return on equity of 28.02%. The business’s quarterly revenue was down 4.0% on a year-over-year basis. During the same period last year, the company posted $1.21 earnings per share. Analysts forecast that Astrazeneca PLC will post $2.97 earnings per share for the current year.
The firm also recently declared a dividend, which was paid on Monday, September 12th. Stockholders of record on Friday, August 12th were given a $0.44 dividend. The ex-dividend date was Wednesday, August 10th. Astrazeneca PLC’s dividend payout ratio (DPR) is currently 78.29%.
Several hedge funds have recently bought and sold shares of AZN. Forester Capital Management LTD raised its stake in Astrazeneca PLC by 68.4% in the first quarter. Forester Capital Management LTD now owns 3,200 shares of the company’s stock valued at $109,000 after buying an additional 1,300 shares during the period. First Interstate Bank raised its stake in Astrazeneca PLC by 233.3% in the second quarter. First Interstate Bank now owns 3,900 shares of the company’s stock valued at $118,000 after buying an additional 2,730 shares during the period. Synovus Financial Corp raised its stake in Astrazeneca PLC by 29.7% in the second quarter. Synovus Financial Corp now owns 4,372 shares of the company’s stock valued at $132,000 after buying an additional 1,000 shares during the period. Fifth Third Bancorp raised its stake in Astrazeneca PLC by 2.3% in the second quarter. Fifth Third Bancorp now owns 4,631 shares of the company’s stock valued at $140,000 after buying an additional 103 shares during the period. Finally, Integrated Investment Consultants LLC raised its stake in Astrazeneca PLC by 6.1% in the second quarter. Integrated Investment Consultants LLC now owns 4,756 shares of the company’s stock valued at $144,000 after buying an additional 275 shares during the period. 11.39% of the stock is currently owned by institutional investors.
Astrazeneca PLC Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.